Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay

PLoS ONE

Volumn 12, Issue 5, 2017, Pages

  Schultz, Heidi S ^a   Reedtz Runge, Stine Louise ^a   Bäckström, B Thomas ^a,b   Lamberth, Kasper ^a   Pedersen, Christian R ^a   Kvarnhammar, Anne M ^a   Deisenhammer, Florian ^c   Christodoulou, Louis ^d   Sikkema, Dan ^e   Loercher, Amy ^e   Davidson, Julie ^e   Lawton, Andy ^e   Etheridge, Steve ^e   Miles, Sally ^e   Pallardy, Marc ^f   Tourdot, Sophie ^f   Mariette, Xavier ^f   Lacroix Desmazes, Sebastien ^f   Broet, Philippe ^f   Bachelet, Delphine ^f   El Hamdi, Nadia ^f   De Vries, Niek ^g   Musters, Anne ^g   Doublet, Aline ^h   Allez, Matthieu ⁱ   Williams, Sabrina ⁱ   Oldenburg, Johannes ^j   Albert, Thilo ^j   Fogdell Hahn, Anna ^k   Ryner, Malin ^k   Ramanujam, Ryan ^k   Hickling, Tim ^l   Bertotti, Elisa ^m   Le Grand, Julie ⁿ   Mauri, Claudia ^o   Jury, Liz ^o   Mikol, Vincent ^p   Hincelin Mery, Agnes ^p   Prades, Catherine ^p   Loas, Pauline ^p   Maggi, Enrico ^q   Karle, Annette ^r   Spindeldreher, Sebastian ^r   Romach Riegraf, Verena ^r   Lanzavecchia, Antonio ^s   Hemmer, Bernhard ^t   Maillere, Bernard ^u   Pedersen, Christian Ross ^a   Dönnes, Pierre ^v   Lo, Jeannette ^w   Buchmann, Pascale ^w   Richard, Fabien ^x   Keipert, Christine ^y   Bertini, Riccardo ^z   Farnetani, Simona ^z   more..

^a NOVO NORDISK A S   (Denmark)

^b BTB Pharma   (Sweden)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UCB PHARMA   (Belgium)

^e GLAXOSMITHKLINE   (United Kingdom)

^f INSERM   (France)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

ⁱ Groupe d'Études Thérapeutiques des Affections Inflammatoires du Tube Digestif   (France)

^j UNIVERSITY HOSPITAL BONN   (Germany)

^k KAROLINSKA INSTITUTE   (Sweden)

^l PFIZER INC   (United States)

^m Merck Serono   (Germany)

ⁿ IPSEN   (France)

^o UNIVERSITY COLLEGE LONDON   (United Kingdom)

^p SANOFI   (France)

^q UNIVERSITY OF FLORENCE   (Italy)

^r Lead Finding Unit   (India)

^s Fondazione per l'Istituto di Ricerca in Biomedicina   (Switzerland)

^t TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^u DIF   (France)

^v Novo Nordisk ^*  (Sweden)

^w BAYER PHARMA AG   (Germany)

^x ETRIKS   (United Kingdom)

^y PAUL EHRLICH INSTITUT   (Germany)

^z ALTA Ricerca e Sviluppo in Biotecnologie Srlu   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYTOMEGALOVIRUS ANTIGEN PP65; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; HLA DRB1 ANTIGEN; INFLIXIMAB; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; NATALIZUMAB; RITUXIMAB; ANTIBODY; HLA ANTIGEN;

ALLELE; ARTICLE; CD4+ T LYMPHOCYTE; CELL ASSAY; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE RELEASE; DONOR; ENZYME LINKED IMMUNOSPOT ASSAY; HAPLOTYPE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; NORMAL HUMAN; QUANTITATIVE ANALYSIS; T CELL PBMC ASSAY; THYMIDINE INCORPORATION ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY;

ANTIBODIES; CD4-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HAPLOTYPES; HLA ANTIGENS; HUMANS; TISSUE DONORS;

EID: 85020042719     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0178544     Document Type: Article

References (58)

1. Tovey MG, Legrand J, Lallemand C. Overcoming immunogenicity associated with the use of biopharmaceuticals. Expert Rev Clin Pharmacol. 2011; 4(5):623-31. https://doi.org/10.1586/ecp.11.39 PMID: 22114889
2. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002; 346(7):469-75. https://doi.org/10.1056/NEJMoa011931 PMID: 11844847
3. Moss AC, Brinks V, Carpenter JF. Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors. Aliment Pharmacol Ther. 2013; 38(10):1188-97. https://doi. org/10.1111/apt.12507 PMID: 24118102
4. Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci. 2011; 100(2):354-87. https://doi.org/10.1002/jps.22276 PMID: 20740683
5. Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Clin Immunol. 2013; 149(3):534-55. https://doi.org/10.1016/j.clim.2013.09.006 PMID: 24263283
6. Pratt KP, Thompson AR. B-cell and T-cell epitopes in anti-factor VIII immune responses. Clin Rev Allergy Immunol. 2009; 37(2):80-95. https://doi.org/10.1007/s12016-009-8120-7 PMID: 19184559
7. Stickler M, Valdes AM, Gebel W, Razo OJ, Faravashi N, Chin R, et al. The HLA-DR2 haplotype is associated with an increased proliferative response to the immunodominant CD4(+) T-cell epitope in human interferon-beta. Genes Immun. 2004; 5(1):1-7. https://doi.org/10.1038/sj.gene.6364027 PMID: 14735143
8. Barbosa MD, Vielmetter J, Chu S, Smith DD, Jacinto J. Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin Immunol. 2006; 118(1):42-50. https://doi.org/10. 1016/j.clim.2005.08.017 PMID: 16260183
9. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self Nonself. 2010; 1(4):314-22. PubMed Central PMCID: PMCPMC3062386. https://doi.org/10.4161/self.1.4.13904 PMID: 21487506
10. Jones TD, Phillips WJ, Smith BJ, Bamford CA, Nayee PD, Baglin TP, et al. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J Thromb Haemost. 2005; 3 (5):991-1000. https://doi.org/10.1111/j.1538-7836.2005.01309.x PMID: 15869596
11. Weber CA, Mehta PJ, Ardito M, Moise L, Martin B, De Groot AS. T cell epitope: friend or foe? Immunogenicity of biologics in context. Adv Drug Deliv Rev. 2009; 61(11):965-76. https://doi.org/10.1016/j. addr.2009.07.001 PMID: 19619593
12. Yeung VP, Chang J, Miller J, Barnett C, Stickler M, Harding FA. Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J Immunol. 2004; 172(11):6658-65. PMID: 15153481
13. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010; 2(3):256-65. PubMed Central PMCID: PMCPMC2881252. PMID: 20400861
14. Wullner D, Zhou L, Bramhall E, Kuck A, Goletz TJ, Swanson S, et al. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clin Immunol. 2010; 137(1):5-14. https://doi.org/10.1016/j.clim.2010.06.018 PMID: 20708973
15. Moser JM, Sassano ER, Leistritz del C, Eatrides JM, Phogat S, Koff W, et al. Optimization of a dendritic cell-based assay for the in vitro priming of naive human CD4+ T cells. J Immunol Methods. 2010; 353 (1-2):8-19. https://doi.org/10.1016/j.jim.2009.11.006 PMID: 19925804
16. Stickler M, Rochanayon N, Razo OJ, Mucha J, Gebel W, Faravashi N, et al. An in vitro human cellbased assay to rank the relative immunogenicity of proteins. Toxicol Sci. 2004; 77(2):280-9. https://doi. org/10.1093/toxsci/kfh021 PMID: 14691215
17. Geiger R, Duhen T, Lanzavecchia A, Sallusto F. Human naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells. J Exp Med. 2009; 206(7):1525-34. PubMed Central PMCID: PMCPMC2715094. https://doi.org/10.1084/jem.20090504 PMID: 19564353
18. Delluc S, Ravot G, Maillere B. Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential. Blood. 2010; 116(22):4542-5. https://doi.org/10. 1182/blood-2010-04-280875 PMID: 20702780
19. Delluc S, Ravot G, Maillere B. Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors. FASEB J. 2011; 25(6):2040-8. https://doi.org/10.1096/fj.10-173872 PMID: 21368101
20. Wang YM, Wang J, Hon YY, Zhou L, Fang L, Ahn HY. Evaluating and Reporting the Immunogenicity Impacts for Biological Products-a Clinical Pharmacology Perspective. AAPS J. 2016; 18(2):395-403. https://doi.org/10.1208/s12248-015-9857-y PMID: 26721560
21. Baker M, Carr F. Pre-clinical considerations in the assessment of immunogenicity for protein therapeutics. Curr Drug Saf. 2010; 5(4):308-13. PMID: 20615174
22. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009; 68(11):1739-45. https://doi.org/10.1136/ard.2008.092833 PMID: 19019895
23. Lundkvist M, Engdahl E, Holmen C, Moverare R, Olsson T, Hillert J, et al. Characterization of anti-natalizumab antibodies in multiple sclerosis patients. Mult Scler. 2013; 19(6):757-64. https://doi.org/10.1177/1352458512462920 PMID: 23045379
24. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004; 50(8):2580-9. https://doi.org/10.1002/art.20430 PMID: 15334472
25. Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol. 2007; 17(3):191-7. https://doi.org/10.1007/s10165-007-0565-z PMID: 17564773
26. Rup B, Pallardy M, Sikkema D, Albert T, Allez M, Broet P, et al. Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. Clin Exp Immunol. 2015; 181 (3):385-400. PubMed Central PMCID: PMCPMC4557374. https://doi.org/10.1111/cei.12652 PMID: 25959571
27. Wolfl M, Greenberg PD. Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells. Nat Protoc. 2014; 9(4):950-66. PubMed Central PMCID: PMCPMC4312138. https://doi. org/10.1038/nprot.2014.064 PMID: 24675735
28. Miller RA. Quantitation of functional T cells by limiting dilution. Curr Protoc Immunol. 2001;Chapter 3: Unit 315.
29. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006; 54(12):3782-9. https://doi.org/10.1002/art. 22214 PMID: 17133559
30. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006; 54(3):711-5. https://doi.org/10.1002/art.21671 PMID: 16508927
31. Eng GP, Bendtzen K, Bliddal H, Stoltenberg M, Szkudlarek M, Fana V, et al. Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study. Arthritis. 2015; 2015:784825. PubMed Central PMCID: PMCPMC4339793. https://doi.org/10.1155/2015/784825 PMID: 25759761
32. Baert F, Noman M, Vermeire S, Van Assche G, G DH, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348(7):601-8. https://doi.org/10.1056/NEJMoa020888 PMID: 12584368
33. Denton CP, Engelhart M, Tvede N, Wilson H, Khan K, Shiwen X, et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2009; 68(9):1433-9. https://doi. org/10.1136/ard.2008.096123 PMID: 18782794
34. de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC, Dijkmans BA, et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis. 2007; 66(9):1252-4. PubMed Central PMCID: PMCPMC1955152. https://doi.org/10.1136/ard.2007.072397 PMID: 17472991
35. Thurlings RM, Teng O, Vos K, Gerlag DM, Aarden L, Stapel SO, et al. Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2010; 69(2):409-12. https://doi.org/10. 1136/ard.2009.109041 PMID: 19596693
36. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum. 2006; 54(9):2970-82. https://doi.org/10.1002/art.22046 PMID: 16947528
37. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum. 2005; 52(9):2740-50. https://doi.org/10.1002/art.21260 PMID: 16142737
38. Schmidt E, Hennig K, Mengede C, Zillikens D, Kromminga A. Immunogenicity of rituximab in patients with severe pemphigus. Clin Immunol. 2009; 132(3):334-41. https://doi.org/10.1016/j.clim.2009.05.007 PMID: 19502112
39. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007; 66(7):921-6. PubMed Central PMCID: PMCPMC1955110. https://doi.org/10.1136/ard.2006.065615 PMID: 17301106
40. Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int. 2007; 27(3):269-74. https://doi.org/10. 1007/s00296-006-0183-7 PMID: 17006705
41. Kneepkens EL, Wei JC, Nurmohamed MT, Yeo KJ, Chen CY, van der Horst-Bruinsma IE, et al. Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. Ann Rheum Dis. 2015; 74(2):396-401. https://doi.org/10.1136/annrheumdis-2013-204185 PMID: 24326011
42. Holmen C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, et al. A Swedish national postmarketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler. 2011; 17 (6):708-19. https://doi.org/10.1177/1352458510394701 PMID: 21228027
43. Joubert MK, Deshpande M, Yang J, Reynolds H, Bryson C, Fogg M, et al. Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics. PLoS One. 2016; 11(8):e0159328. https://doi.org/10.1371/journal.pone.0159328 PMID: 27494246
44. Jenkins MK, Moon JJ. The role of naive T cell precursor frequency and recruitment in dictating immune response magnitude. J Immunol. 2012; 188(9):4135-40. PubMed Central PMCID: PMCPMC3334329. https://doi.org/10.4049/jimmunol.1102661 PMID: 22517866
45. Maillere B. Comment on "The role of naive T cell precursor frequency and recruitment in dictating immune response magnitude". J Immunol. 2013; 190(5):1895. https://doi.org/10.4049/jimmunol. 1290079 PMID: 23417524
46. Mannering SI, Morris JS, Jensen KP, Purcell AW, Honeyman MC, van Endert PM, et al. A sensitive method for detecting proliferation of rare autoantigen-specific human T cells. J Immunol Methods. 2003; 283(1-2):173-83. PMID: 14659909
47. Karlsson AC, Martin JN, Younger SR, Bredt BM, Epling L, Ronquillo R, et al. Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods. 2003; 283(1-2):141-53. PMID: 14659906
48. Anthony DD, Milkovich KA, Zhang W, Rodriguez B, Yonkers NL, Tary-Lehmann M, et al. Dissecting the T Cell Response: Proliferation Assays vs. Cytokine Signatures by ELISPOT. Cells. 2012; 1(2):127-40. PubMed Central PMCID: PMCPMC3901088. https://doi.org/10.3390/cells1020127 PMID: 24710419
49. Mascarenhas RE, Brodskyn C, Barbosa G, Clarencio J, Andrade-Filho AS, Figueiroa F, et al. Peripheral blood mononuclear cells from individuals infected with human T-cell lymphotropic virus type 1 have a reduced capacity to respond to recall antigens. Clin Vaccine Immunol. 2006; 13(5):547-52. PubMed Central PMCID: PMCPMC1459653. https://doi.org/10.1128/CVI.13.5.547-552.2006 PMID: 16682474
50. Karle A, Spindeldreher S, Kolbinger F. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. MAbs. 2016; 8(3):536-50. https://doi.org/10.1080/19420862.2015.1136761 PMID: 26817498
51. Gebel HM, Scott JR, Parvin CA, Rodey GE. In vitro immunization to KLH. II. Limiting dilution analysis of antigen-reactive cells in primary and secondary culture. J Immunol. 1983; 130(1):29-32. PMID: 6183352
52. van Schie KA, Wolbink GJ, Rispens T. Cross-reactive and pre-existing antibodies to therapeutic antibodies - Effects on treatment and immunogenicity. MAbs. 2015; 7(4):662-71. PubMed Central PMCID: PMCPMC4623040. https://doi.org/10.1080/19420862.2015.1048411 PMID: 25962087
53. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998; 16(8):2825-33. https://doi.org/10.1200/JCO.1998.16. 8.2825 PMID: 9704735
54. Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1999; 10(6):655-61. PMID: 10442187
55. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009; 9(4):271-85. PubMed Central PMCID: PMCPMC2737409. https://doi.org/10.1038/nri2526 PMID: 19319144
56. de Andres C, Teijeiro R, Alonso B, Sanchez-Madrid F, Martinez ML, Guzman de Villoria J, et al. Longterm decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis. PLoS One. 2012; 7(4):e34103. PubMed Central PMCID: PMCPMC3319565. https://doi.org/10.1371/journal.pone.0034103 PMID: 22496780
57. Baldwin HM, Ito-Ihara T, Isaacs JD, Hilkens CM. Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis. Ann Rheum Dis. 2010; 69(6):1200-7. https://doi. org/10.1136/ard.2009.110502 PMID: 19773288
58. Dahlén R, Strid H, Lundgren A, Isaksson S, Raghavan S, Magnusson MK, et al. Infliximab Inhibits Activation and Effector Functions of Peripheral Blood T Cells in vitro from Patients with Clinically Active Ulcerative Colitis. Scandinavian Journal of Immunology. 2013; 78(3):275-84. https://doi.org/10.1111/sji.12081 PMID: 23713660